226
Participants
Start Date
March 18, 2022
Primary Completion Date
July 23, 2024
Study Completion Date
November 15, 2024
Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)
"Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator."
Placebo administration
"For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator."
Neuro-Urology-Andrology, Physical Medicine and Rehabilitation Department, Raymond Poincaré Hospital, APHP, Garches
Assistance Publique - Hôpitaux de Paris
OTHER